CSCB Virtual Seminar Series

Epigenetic mechanisms of resistance to anti-HER2 therapy in breast cancer

Date: 1st March 2021 (Monday)
Time: 12noon-1.00pm (SGT)

Venue: *via* **Zoom**
For details, please contact:
Lilian Poon – lilian.poon@duke-nus.edu.sg or +65 6601 3779

Abstract:

HER2-targeted therapy had significantly improved the prognosis of patients with HER2+ breast cancer. However, nearly half of such patients still suffer disease relapse due to intrinsic or acquired resistance to the treatments. HER2-targeting therapies such as trastuzumab exert the antitumor response through antagonizing the oncogenic HER2 signaling and eliciting antitumor immunity. Our recent work has begun to reveal the role of epigenetics in anti-HER2 resistance. We found that epigenetics not only contributes to the inactivation of the tumor suppressor pathway but also modulates the immune response to anti-HER2 therapy. Targeting the epigenetic mechanism can sensitize anti-HER2 treatment, potentially providing an opportunity to mitigate anti-HER2 resistance.

Speaker:

Professor Yu Qiang

Senior Group Leader, Lab of Precision Cancer Medicine, Genome Institute of Singapore
Adjunct Professor, Program in Cancer & Stem Cell Biology, Duke-NUS Medical School

Dr. Yu Qiang is a senior group leader at Genome Institute of Singapore, where his lab works on projects on cancer targets and biomarkers discoveries in support of the development and implementation of A*STAR's R&D strategies on translational cancer research. He also holds adjunct professorships in NUS and DUKE-NUS. His primary research interests include epigenetic mechanisms of therapy resistance and developing innovative therapeutic strategies for cancer, which have been widely published in scientific journals including *Nature Medicine, Cancer Cell, Molecular Cell, Cancer Discovery, JCI, JEM, PNAS, etc.*

Host:
SHANG Li
Associate Professor
Programme in Cancer & Stem Cell Biology
Duke-NUS Medical School, Singapore

No registration is required.
All are welcome.